(Q52565403)

3 May 2018

title

RDP58 is a novel and potentially effective oral therapy for ulcerative colitis. (English)

1 reference

3 May 2018

author name string

Simon Travis

1

1 reference

3 May 2018

Lee Min Yap

2

1 reference

3 May 2018

Chris Hawkey

3

1 reference

3 May 2018

Bryan Warren

4

1 reference

3 May 2018

Mirella Lazarov

5

1 reference

3 May 2018

Tim Fong

6

1 reference

3 May 2018

R J Tesi

7

1 reference

3 May 2018

RDP Investigators Study Group

8

1 reference

3 May 2018

publication date

1 August 2005

1 reference

3 May 2018

Inflammatory Bowel Diseases

published in

1 reference

3 May 2018

volume

11

1 reference

3 May 2018

issue

8

1 reference

3 May 2018

page(s)

713-719

1 reference

3 May 2018

Rational design and development of RDP58.

cites work

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000172807.26748.16

RDP58, a locally active TNF inhibitor, is effective in the dextran sulphate mouse model of chronic colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000172807.26748.16

RDP58, a novel immunomodulatory peptide with anti-inflammatory effects. A pharmacological study in trinitrobenzene sulphonic acid colitis and Crohn disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000172807.26748.16

MyD88: an adapter that recruits IRAK to the IL-1 receptor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000172807.26748.16

IL-1-induced NFkappa B and c-Jun N-terminal kinase (JNK) activation diverge at IL-1 receptor-associated kinase (IRAK)

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000172807.26748.16

Inhibition of tumor necrosis factor mRNA translation by a rationally designed immunomodulatory peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000172807.26748.16

RDP58, a novel immunomodulatory peptide, ameliorates clinical signs of disease in the Lewis rat model of acute experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000172807.26748.16

Oral RDP58 allows CPT-11 dose intensification for enhanced tumor response by decreasing gastrointestinal toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000172807.26748.16

A simple clinical colitis activity index

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000172807.26748.16

Cortisone in ulcerative colitis; final report on a therapeutic trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000172807.26748.16

A reproducible grading scale for histological assessment of inflammation in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000172807.26748.16

A Comparison of Oral Prednisolone Given as Single or Multiple Daily Doses for Active Proctocolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000172807.26748.16

Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000172807.26748.16

Fluticasone reduces IL-6 and IL-8 production of cystic fibrosis bronchial epithelial cells via IKK-beta kinase pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000172807.26748.16

10.1097/01.MIB.0000172807.26748.16

21 January 2018

Identifiers

DOI

1 reference

3 May 2018

1 reference

3 May 2018